FDA, Zepbound and obstructive sleep apnea

Zepbound Gets FDA Approval to Treat Sleep Apnea
The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA announced today.
FDA approves first-ever medication for obstructive sleep apnea
“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical Care at the FDA’s Center for Drug Evaluation and Research.
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the first medication for certain patients with the condition.
FDA approves first medication for obstructive sleep apnea, which also promotes weight loss
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.
F.D.A. Approves Weight Loss Drug to Treat Obstructive Sleep Apnea
Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration on Friday approved the weight loss drug Zepbound to treat obstructive sleep apnea. It is the first prescription medication approved to treat the common sleep disorder.
Zepbound Weight Loss Medication Approved by FDA to Treat Sleep Apnea
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat obstructive sleep apnea.
Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity
The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.
The popular weight-loss drug Zepbound can now be used to treat sleep apnea
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.
Weight Loss Drug Tirzepatide Now Approved for Sleep Apnea in Adults With Obesity
The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.
Zepbound Approved for Obstructive Sleep Apnea in Patients With Obesity
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
FDA approves new drug for sleep apnea
The drug is known as Zepbound and is the same as the chemical drug Tirzepatide. "See To Believe uncovers the forgotten, mind-blowing facts that will leave you questioning everything. Follow wild stories of mysterious creatures,
Inquirer on MSN1d
US approves first-ever obstructive sleep apnea drug
On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...
Everyday Health5d
FDA Approves First Medication for Obstructive Sleep Apnea
By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...
Sleep apnea? Neuro implants promise good night’s rest
WAKE-UP CALL: 104m Indians or 11% of the population suffer from obstructive sleep apnea, according to a 2023 AIIMS study ...